January 30, 2018 08:17 AM EST

Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap

John Carroll

Editor & Founder

Anyone shopping for some early- and mid-stage neurosciences programs should look over the menu of discontinued programs out from Pfizer $PFE this morning. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap

John Carroll

Editor & Founder

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Pfiz­er sweeps out a line­up of neu­ro­science drugs — as well as can­cer and NASH pro­grams — in­to the scrap heap

John Carroll

Editor & Founder

Sign up to read this article for free.

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?